Stockreport

Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... [Yahoo! Finance]

Mind Medicine (MindMed) Inc. - Common Shares  (MNMD) 
PDF Research and Development Expenses: $17.2 million for the quarter ended September 30, 2024, up from $13.2 million for the same period in 2023. General and Administrati [Read more]